Maribavir versus investigator assigned therapy: Exploring the exploratory.
Publication
, Journal Article
Heldman, MR; Limaye, AP
Published in: Transpl Infect Dis
June 2023
Duke Scholars
Published In
Transpl Infect Dis
DOI
EISSN
1399-3062
Publication Date
June 2023
Volume
25
Issue
3
Start / End Page
e14063
Location
Denmark
Related Subject Headings
- Surgery
- Humans
- Cytomegalovirus Infections
- Antiviral Agents
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Heldman, M. R., & Limaye, A. P. (2023). Maribavir versus investigator assigned therapy: Exploring the exploratory. Transpl Infect Dis, 25(3), e14063. https://doi.org/10.1111/tid.14063
Heldman, Madeleine R., and Ajit P. Limaye. “Maribavir versus investigator assigned therapy: Exploring the exploratory.” Transpl Infect Dis 25, no. 3 (June 2023): e14063. https://doi.org/10.1111/tid.14063.
Heldman MR, Limaye AP. Maribavir versus investigator assigned therapy: Exploring the exploratory. Transpl Infect Dis. 2023 Jun;25(3):e14063.
Heldman, Madeleine R., and Ajit P. Limaye. “Maribavir versus investigator assigned therapy: Exploring the exploratory.” Transpl Infect Dis, vol. 25, no. 3, June 2023, p. e14063. Pubmed, doi:10.1111/tid.14063.
Heldman MR, Limaye AP. Maribavir versus investigator assigned therapy: Exploring the exploratory. Transpl Infect Dis. 2023 Jun;25(3):e14063.
Published In
Transpl Infect Dis
DOI
EISSN
1399-3062
Publication Date
June 2023
Volume
25
Issue
3
Start / End Page
e14063
Location
Denmark
Related Subject Headings
- Surgery
- Humans
- Cytomegalovirus Infections
- Antiviral Agents
- 3202 Clinical sciences
- 1103 Clinical Sciences